Median

Purpose

To compare the short term, long term and nutritional benefits of the Metanx vs placebo in patients with Diabetic Peripheral Neuropathy

Criteria

Contact Principal Investigator for Information

Details

Patients ages 25-80 that have a diagnosis of diabetic peripheral neuropathy for at least 6 months but less than 7 years will be enrolled.  Patients will be randomly assigned to Metanx or placebo once enrolled.  Metanx is classified as a medical food.  Patients will complete quality of life questionnaires, have lab samples taken, skin punch biopsy  and undergo EKG's at designated visits.

Interested in more information? Contact Us:

Jason Milligan, M.D., Principal Investigator
(318) 212-8130

IRB: Copernicus
IRB Number:
Trial Type: Drug
Sponsor: PamLab